Recombinant monoclonal antibody to IL23A. Brazikumab is a human monoclonal antibody that can be potentially used in the treatment of Crohn's disease (CD).
Figure 1 Anti-Human IL23A Therapeutic Antibody (Brazikumab) (TAB-008ML) in SDS-PAGE
SDS-PAGE analysis of TAB-008ML in non-reduced (Lane 1) and reduced (Lane 2) conditions. Gel stained for 30 minutes with Coomassie Blue. As a result of different β-mercaptoethanol-reduced proteins (Heavy chain and Light chain) migrate as about 50 kDa and 25 kDa, respectively. And non-reduced protein migrates as 130-180 kDa.
Figure 2 Anti-Human IL23A Therapeutic Antibody (Brazikumab) (TAB-008ML) in SEC-HPLC
HPLC analysis of TAB-008ML shows the purity is>95%.
Figure 3 Anti-Human IL23A Therapeutic Antibody (Brazikumab) (TAB-008ML) in WB
Western blot analysis was performed by loading 0.1 µg (lane 1), 0.3 µg (lane 2), and 0.6 µg (lane 3) recombinant human IL23 protein onto a 12% Tris-HCl polyacrylamide gel. Proteins were transferred to a CN membrane and blocked with 5% skim milk for at least 1 hour. Membranes were probed with Anti-Human IL23A Therapeutic Antibody (Brazikumab) (TAB-008ML) at a dilution of 1:500 overnight at 4°C on a rocking platform. Then probed with SA-HRP secondary antibody. Chemiluminescent was detected.
Lane 1: Reducing antigen (0.1 μg)
Lane 2: Reducing antigen (0.3 μg)
Lane 3: Reducing antigen (0.6 μg)
Figure 4 Anti-Human IL23A Therapeutic Antibody (Brazikumab) (TAB-008ML) in DB
Dot Blot analysis of TAB-008ML was performed by coating with human IL4R protein antigen.
TAB-008ML incubation concentration: 2 ng/μL.
The secondary antibody: SA-HRP
Figure 5 Anti-Human IL23A Therapeutic Antibody (Brazikumab) (TAB-008ML) in ELISA
ELISA analysis of TAB-008ML was performed by coating with recombinant human IL23a antigen. Then blocked with BSA and incubated with Anti-Human IL23A Therapeutic Antibody (Brazikumab) (TAB-008ML). The SA-HRP as a secondary antibody. Detection was performed using TMB substrate and stopped with sulfuric acid. The absorbances were read on a spectrophotometer at 450 nm.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Afuco™ Anti-IL23A ADCC Recombinant Antibody, ADCC Enhanced (AFC-TAB-008ML)This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to IL23A. It is a human monoclonal antibody that can be potentially used in the treatment of Crohn's disease (CD).
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
NAB-1953-VHH | Recombinant Anti-human IL23A VHH Single Domain Antibody | WB, IP, ICC, FC, FA | Llama VHH |
TAB-005LC-VHH | Anti-human IL23A Recombinant Antibody (TAB-005LC-VHH) | ELISA | Single domain antibody |
There are currently no Customer reviews or questions for TAB-008ML. Click the button above to contact us or submit your feedback about this product.
To accurately reference this product in your publication, please use the following citation information:
(Creative Biolabs Cat# TAB-008ML, RRID: AB_3111736)
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.